Coverage of Alzheimer's drug Aduhelm limited due to concerns about effectiveness, safety | WFAE 90.7
Aduhelm, an expensive Alzheimer's drug, is fomenting controversy — and generating excitement for patients. The FDA approved it last summer. But Adulem’s results are the subject of intense debate — and so is the cost of the drug.
Source: wfae.org